Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Sells $185,460.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Tia L. Bush sold 11,000 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total transaction of $185,460.00. Following the transaction, the chief technology officer now directly owns 121,503 shares of the company’s stock, valued at approximately $2,048,540.58. This trade represents a 8.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Centessa Pharmaceuticals Stock Up 3.5 %

CNTA stock opened at $17.84 on Friday. The firm’s 50-day moving average is $16.74 and its two-hundred day moving average is $15.30. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -11.66 and a beta of 1.53. Centessa Pharmaceuticals plc has a 52 week low of $7.38 and a 52 week high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. On average, analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Guggenheim boosted their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 15th. TD Cowen initiated coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $25.83.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CNTA. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after acquiring an additional 826 shares during the last quarter. GAMMA Investing LLC lifted its stake in Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares during the last quarter. Atria Investments Inc boosted its holdings in Centessa Pharmaceuticals by 7.0% during the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock worth $274,000 after buying an additional 1,116 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Centessa Pharmaceuticals by 39.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock worth $317,000 after buying an additional 5,316 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in Centessa Pharmaceuticals in the third quarter worth approximately $187,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.